Industry Involvement

The Organising Committee would like to thank the following companies whose continued support in the provision of unrestricted educational funding has been of great value in establishing the HIV & Hepatitis in the Americas Congress.


Gilead Logo

333 Lakeside Drive
Foster City, CA 94404, USA

For over 30 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world. Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions. Every day we strive to transform and simplify care for people with life-threatening illnesses.

GlaxoSmithKline Argentina Sa
Carlos Casares 3690, Victoria, Buenos Aires (1644), Argentina

ViiV Healthcare LLC is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV.

2000 Galloping Hill Road,
Kenilworth, NJ 07033, USA

Our Commitment to HIV
For more than 30 years MSD, known as Merck & Co Inc. in the US and Canada, has been committed to scientific research and discovery in HIV and we continue to be driven by the conviction that more medical advances are still to come. Our focus is on pursuing research that addresses unmet medical needs and helps people living with HIV and their communities. We are making choices, including in our HIV pipeline, that could potentially change the HIV treatment and prevention paradigms, and help bring us closer to the goal of finding a cure. We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges to continued progress. For more information, visit